gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NVAXHealthcareBiotechnology

Novavax Inc (NVAX)

$10.65+10.02%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$10.65▲ 41.81% in range
Nov 4, 2025Low $6.22 · High $12.82Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Novavax closed at $10.65 on Nov 4, up 10.02%, 16.9% below its 52-week closing high. Volume of 6.0M shares was 0.85× its 20-day average (close to normal).

Split-adjusted performance: -5.9% over one month, +13.8% over six months, +34.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $56.70M, down 76.3% from a year earlier, with a net margin of -94.2%.

Short interest was 47.3M shares at the Oct 15 settlement, up 2.8% from the prior report (30.3% of float, 4.3 days to cover).

Market cap$1.76B164.9M shares
Revenue · quarter$56.7M−76.3% YoY
Diluted EPS$-0.32−151.6% YoY
P/E · TTM—P/S 4.2×
Net margin-94.2%Gross 74.9%
Dividend yieldNone$0.1062 last paid
52-week range6.22 – 12.82−16.9% from high
Volume6.0M0.85× 20-day avg
Volatility · 60d82.7%Annualised
Short % of float30.3%4.3 days to cover
Net cash$422.0MCash $719.3M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.2%1M −5.9%3M +37.6%6M +13.8%YTD +58.5%1Y +34.6%3Y +63.3%5Y −92.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum75
Revenue growth15
Net margin62
Value (low P/E)—
Size75

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short47.3M+2.8% vs prior
Days to cover4.3Settled Oct 15
% of float30.3%
Short vol. 10d50.9%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NVAXNovavax$10.65+10.02%+13.8%−76.3%−94.2%—$1.76B
MAZEMaze Therapeutics$33.38+3.50%+26.1%———$1.85BCompare
REPLReplimune Group$20.69+0.19%+501.5%———$1.96BCompare
VIRVir Biotechnology$11.77+4.90%+14.4%+19582.5%33.5%—$1.99BCompare
BCRXBioCryst Pharmaceuticals$8.24−3.85%−6.7%+33.6%35.9%—$2.11BCompare
COAGHemab Therapeutics Holdings$45.09+4.62%————$2.11BCompare
TSHATaysha Gene Therapies$4.36+6.60%−37.5%−100.0%——$1.42BCompare
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32BCompare
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare

News about Novavax

All news →
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research · Oct 26, 2026▼ NegativeInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowZacks Investment Research · Oct 21, 2026NeutralNovavax (NVAX) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research · Oct 19, 2026▼ NegativeNovavax (NVAX) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research · Oct 13, 2026NeutralNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research · Oct 9, 2026Neutral

Quick answers

What does Novavax do?
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
What is NVAX's market cap?
$1.76B, based on the Nov 4 close of $10.65.
Does Novavax pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NVAX is sold short?
47.3M shares, 30.3% of float, as of Oct 15, 2026.
What sector is NVAX in?
Healthcare, in the Biotechnology industry.

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

HQ: Gaithersburg, MD749 employeesListed Dec 5, 1995novavax.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology